Clinical Trials in Sweden: Enhancing Competence and Promoting Innovation
In a presentation presented at COG Nordics 2024, Gunilla Andrew-Nielsen, Head of the Clinical Trials and Innovation Centre at the Swedish Medical Products Agency (MPA), highlighted the importance of clinical trials for Sweden in offering patients access to modern, high-quality care and new treatments. The presentation, delivered on February 9, 2024, outlined several key initiatives undertaken by the MPA to support and promote clinical trials in the country.
Andrew-Nielsen discussed two crucial government assignments given to the MPA. The first, commissioned in October 2023, focuses on implementing competence-enhancing measures to promote clinical trials in Sweden, with a probable launch in mid-2024. The second, assigned in March 2024, tasks the MPA with compiling and providing statistics on clinical trials at a national level to maximize the benefit of available information and existing knowledge.
The MPA's efforts to support innovation rest on three pillars: information and training, regulatory and scientific advice, and regulatory science. The agency organizes various events, such as lunch seminars on drug development, a two-day conference on clinical trials, and provides informative content through its website and newsletters. Additionally, the MPA offers "Meet-Your-Regulator" sessions, simultaneous national scientific advice, and collaborates with Swedish universities and other national competent authorities in the EU on regulatory science projects.
The establishment of the MPA's Innovation Office aims to simplify access to the agency, increase regulatory knowledge among researchers and innovators, and ensure that the MPA provides its regulatory and scientific advice to small and medium-sized enterprises (SMEs) and academic research groups. The Innovation Office supports the Swedish National Life Science strategy and can be reached through its dedicated website: https://www.lakemedelsverket.se/sv/tillstand-godkannande-och-kontroll/radgivning/innovationsstod
As Sweden continues to prioritize clinical trials and innovation in the life sciences sector, the MPA's initiatives, led by experts like Gunilla Andrew-Nielsen, play a crucial role in enhancing competence, promoting collaboration, and ultimately improving patient access to innovative treatments.
Missed this one? Join our next European meeting in Amsterdam this November, full details here: https://www.thepbcgroup.com/cog-europeÂ